High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma-Reference-Cited by-同舟云学术

High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma

Published:2016-08-12 Issue:4 Volume:469 Page:427-434
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Nguyen Doreen,Taheri Diana,Springer Simeon,Cowan Morgan,Guner Gunes,Mendoza Rodriguez Maria Angelica,Wang Yuxuan,Kinde Isaac,VandenBussche Christopher J.,Olson Matthew T.,Ricardo Bernardo F. P.,Cunha Isabela,Fujita Kazutoshi,Ertoy Dilek,Kinzler Kenneth W.,Bivalacqua Trinity J.,Papadopoulos Nickolas,Vogelstein Bert,Netto George J.

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00428-016-2001-2.pdf

Reference30 articles.

1. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van d, Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, RG M, Kogevinas M, EW S, AA v T, Abas C, TF O, TC Z, Malats N, EC Z, Real FX (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65:360–366. doi: 10.1016/j.eururo.2013.08.052

2. Amin MB, Ro JY, el-Sharkawy T, Lee KM, Troncoso P, Silva EG, Ordonez NG, Ayala AG (1994) Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18:1224–1232

3. MB A, SC S, Reuter VE, Epstein JI, DJ G, DE H, Lin O, JK MK, Montironi R, GP P, HA A-A, Algaba F, Ali S, Alvarado-Cabrero I, Bubendorf L, Cheng L, JC C, Kristiansen G, RJ C, Delahunt B, JN E, EM G, Gulmann C, Hartmann A, Langner C, Lopez-Beltran A, Magi-Galluzzi C, Merce J, GJ N, Oliva E, Rao P, JY R, JR S, SK T, Tsuzuki T, SA U, der Kwast T V, RH Y, MS S (2015) Update for the practicing pathologist: the international consultation on urologic disease-European association of urology consultation on bladder cancer modern pathology. An Official Journal of the United States and Canadian Academy of Pathology, Inc 28:612–630. doi: 10.1038/modpathol.2014.158

4. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, Wiencke JK, Wrensch MR, Chang SM, Walsh KM, Myong S, Song JS, Costello JF (2015) Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348:1036–1039. doi: 10.1126/science.aab0015

5. Black PC, Brown GA, Dinney CP (2009) The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 27:3–7. doi: 10.1016/j.urolonc.2007.07.010

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular profile of bladder cancer progression to clinically aggressive subtypes;Nature Reviews Urology;2024-02-06

2. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study;Urologic Oncology: Seminars and Original Investigations;2023-12

3. Molecular Pathology of Micropapillary Carcinomas: Is Characteristic Morphology Related to Molecular Mechanisms?;Applied Immunohistochemistry & Molecular Morphology;2023-04-11

4. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management;Human Pathology;2023-03

5. Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer;Scientific Reports;2022-10-05